Table 4 Modulation of cytotoxicity by zosuquidar and the P-gp activity in 31 patient cells
From: Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML)
RMF | Uptake | ||||
|---|---|---|---|---|---|
Resistance Modifiding | DNR/Ida | MITOX | Mylotarg | DIOC2 +Zosu | |
P01 | No | 1.1 | 0.6 | 1.0 | 0.06 |
P02 | Yes/DNR, Ida, Mylotarg | 2.3/3.2 | 20% | 35%e | 0.53 |
P03 | No | 0.7 | ND | 0.8 | 0.05 |
P04 | No | 0.8 | ND | 1.3 | 0.1 |
P05 | No | 1.1 | 0.92 | 1.1 | 0.05 |
P06 | Yes/Mylotarg | ND | ND | 4.1 | 0.7 |
P07 | Yes/Mylotarg | 1.6 | ND | 29% | 0.46 |
P08 | No | 1.0 | ND | 1.2 | 0.13 |
P09 | No | 0.7/1.2 | ND | 1.0 | 0.24 |
P10 | No | 1.0/1.0 | ND | 1.0 | 0.33 |
P11 | No | 0.9 | ND | 13% | 0.4 |
P12 | Yes/MITOX | ND | 2.1 | ND | 0.6 |
P13 | No | 0.9 | 1.1 | 0.9 | 0.13 |
P14 | No | 1.1 | ND | ND | 0.23 |
P15 | No | 1.1 | 1.3 | 1.0 | 0.13 |
P16 | Yes/DNR, Mitox | 6.6 | 2.1 | ND | 0.04 |
P17 | No | 1.0 | 1.0 | 0.9 | 0.05 |
P18 | No | 1.1 | 0.9 | 1.0 | 0.06 |
P19 | No | 1.0 | 1.0 | 1.0 | 0 |
P20 | Yes/DNR, Mylotarg | 1.4 | ND | 3 | 0.38 |
P21 | No | ND | ND | 0.5 | 0.12 |
P22 | No | 1.2 | 1 | 1 | 0.21 |
P23 | No | 1.1 | 1.0 | 1.0 | 0.21 |
P24 | No | ND | ND | 1.1 | 0.06 |
P25 | Yes/DNR, Mitox, Mylo | 2.5 | 2.3 | 30% | 0.05 |
P26 | No | 1 | ND | ND | 0.04 |
P27 | No | 0.87 | 0.82 | ND | 0.24 |
P28 | No | 0.7 | 1.2 | ND | 0 |
P29 | Yes/Mylotarg | ND | ND | 2.0 | 0.04 |
P30 | No | 1.0 | 1.1 | 1.0 | 0.08 |
P31 | No | 1.2 | ND | 9% | 0.26 |